-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Integrated Biopharma Inc quarterly/annual Deferred Federal Income Tax Expense (Benefit) history and growth rate from Q3 2020 to Q2 2025.
- Integrated Biopharma Inc Deferred Federal Income Tax Expense (Benefit) for the quarter ending June 30, 2025 was $735K, a 550% increase year-over-year.
- Integrated Biopharma Inc Deferred Federal Income Tax Expense (Benefit) for the twelve months ending June 30, 2025 was $1.39M, a 1018% increase year-over-year.
- Integrated Biopharma Inc annual Deferred Federal Income Tax Expense (Benefit) for 2025 was $1.39M, a 1018% increase from 2024.
- Integrated Biopharma Inc annual Deferred Federal Income Tax Expense (Benefit) for 2024 was $124K, a 125% increase from 2023.
Deferred Federal Income Tax Expense (Benefit), Trailing 12 Months (USD)
Deferred Federal Income Tax Expense (Benefit), Quarterly (USD)
Deferred Federal Income Tax Expense (Benefit), YoY Quarterly Growth (%)